These two penny stocks could jump more than 300 percent, analysts said.
Risk and reward often travel together, making the stock market both rich and dangerous. Among the best examples of this axiom are penny stocks, those stocks are priced at $ 5 or less. With that low price, there is great potential for profit, as a small price increase will result in a high percentage gain.Eduardo Lecubarri, JPMorgan̵7;s head of small-cap strategy and midcap sees both opportunity and danger. In the current market environment – and the potential for small stocks that still have room to run, “Q1 may be solid after strong gains since November and the fact that valuations are on top. Forever However, the long-term outlook for the whole year is encouraging given the more powerful underlying wind loads. Such a positive backdrop will likely keep investors chasing a handful of stocks that are still promising a substantial recovery as they appear to be starting YTDs. For this reason, we recommend that investors build their portfolios. For now and look at things in case there are any consolidation procedures that might take place in Q1, ”Lecubarri wrote. Considering the risks, we use TipRanks’ database to find the cool stuff. Penny stocks with a bargain price tag The platform leads us to two symbols with consensus ratings. “Buy Strong” from the analyst community. Not to mention major upside potential is on the table. We’re talking at least 300% yield over the next 12 months, according to analysts, ExcelRx Pharmaceuticals (ACRX) Opioids have made headlines in recent years and for all the wrong reasons. These powerful pain relievers are also dangerously addictive substances that have led to the opioid epidemic in the United States. AcelRx is a pharmaceutical company dedicated to creating safer therapies for Acute Pain Developed a synthetic opioid for sublingual (under the tongue) administration, Sufentanil’s flagship product was approved by the FDA under the brand name Dsuvia in 2018 and by the European Union as Dzuveo. The second under the tongue, Zalviso, is also approved for use by the European Union and is in phase 3 trials in the United States.In its latest earnings report, the $ 1.4 million company ranks the highest, driven by $ 1.3 million in product sales, sales figures were up 433%, respectively, and total revenue figures were up 133% year-over-year against this backdrop.Many Street members believe ACRX’s $ 1.40 share price looks like a steal. Brandon Folkes analysts are upbeat. The prospect of Dsuvia is an alternative to opioid therapy today, and he believes its potential will help increase the company’s stock. ”With the release of Dsuvia, we believe the focus of Investors can turn to the launch of the metrics and the highest sales potential for the product as ACRX launches a real alternative to IV opioids.We expect investors to begin to see the value of the product.We believe Dsuvia offers a breakthrough. To provide adequate pain treatment without the need for invasive and time-consuming IV settings in the emergency room, including outpatient or postoperative settings. Although the hospital opening was time-consuming. But we expect the use of Dsuvia to drive higher than Street’s current projected revenue, which, in turn, could push the stock up from current levels, ”Follked said in line with the stance. At his good, Folkes scores an ACRX Buy, and his $ 9 price target indicates a remarkable 552% upshot chance over the next 12 months. (To view Folkes’ track record, click here.) Switch Now to the rest of Street, 3 have been published, bought and no hold or sell in the last three months, so the ACRX has a consensus rating. Strong Based on a $ 7 average target price, the stock could soar 407% over the next year (see ACRX stock analysis on TipRanks). NuCana (NCNA) NuCana is a biopharma company focused on new cancer treatments. An effective treatment for cancer of the biliary tract, breast, colon and rectum, ovary and pancreas, avoiding the complications and side effects of current chemotherapy, NuCana uses a so-called phosphoramate chemical technology. ProTide to create a class of drugs that will transcend existing nucleotide analog limits behind many chemotherapy drugs, NuCana’s ProTides, have been used in Gilead’s Antiviral Sovaldi last month. Last May, NuCana announced the start of a Phase III trial with Acelarin, the farthest drug candidate along the company’s pipeline for biliary tract cancer. The study covers more than 800 patients in six countries and is ongoing. In November, the company released data described as ‘encouraging’ from a Phase Ib study of the same drug.While Acelarin is the main drug in the NuCana pipeline, two more opportunities are under development, NUC-3373 is in. A phase I trial to treat solid tumors and colon cancer and NUC-7738 is the second route under investigation for its application to advanced solid tumors. Of the three, the colorectal study is the most advanced, writes 5-star analyst Robyn Karnauskas from Truist, looking at the pipeline as the key to NuCana’s investor potential. That NCNA is a platform company that we believe Pass the audit as determined by the clinical product manufacture. We love bringing in 3 products to the clinic, including one new drug and two improved chemotherapy drugs.The data suggests that the platform works and can produce better chemicals. […] While most investors focus on Acelarin, we believe investors should pay more attention to the NUC-3373, another key focus of our platform dissertation with information expected in 1H2021 ”Karnauskas. To this end, Karnauskas set a price target of $ 22 on NCNA, pointing out that the stock has a room for growth of 384% forward, along with a buy rating. (To view Karnauskas’ bio, click here.) Overall, NCNA’s Strong Buy consensus rating is unanimous and based on four recent reviews. The stock has an average price target of $ 17.33, recommending a 270% one-year upside to its current trading price of $ 4.69 (see NCNA stock analysis on TipRanks). To find a good idea for trading penny stocks at It’s interesting to visit TipRanks’ Best Stocks to Buy, a newly released tool that gathers all the insights of TipRanks. Disclaimer: The opinions expressed in this article are: It belongs only to outstanding analysts. This content is for informational purposes only. It is very important to do your own analysis before making any investments.